Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSDC-0160 in mild Alzheimer's disease
NCT01374438Phase 2Completed
- Sponsor
- Metabolic Solutions Development Company
- Start
- Jul 2011
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Mitoglitazone in Alzheimer's disease (AD), sponsored by Metabolic Solutions Development Company. Started Jul 2011; status: completed.
02
Drugs
Mitoglitazone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01374438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01374438.